BioCentury
ARTICLE | Cover Story

MRSA sensitivity training

April 5, 2012 7:00 AM UTC

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity.1 The findings suggest it may now be possible to use combinations of antibiotics to treat infections previously considered intractable.

Methicillin-resistant S. aureus (MRSA) infections are the most frequent cause of skin and soft tissue infections seen in the emergency room in the U.S. In addition, MRSA accounts for about 20% of bloodstream infections in hospital settings.2...